Our current study indicates that Bmi-1 modulates the NF-kappaB/MMP-9 signaling pathway to mediate an aggressive phenotype in human glioma, suggesting that Bmi-1 may represent a potential therapeutic target for the treatment of glioma. The gene discussed is MMP9; the disease is glioma.